Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326217 | 0.86 | KDM4E (0.60) | KDM4EPKMTGFBR1KDM1AGPR119 | |
| SCHEMBL31184445 | 0.85 | KDM4E (0.53) | KDM4EPKMGPR119STSPTPN2 | |
| SCHEMBL2604335 | 0.85 | KDM4E (0.53) | KDM4EPKMGPR119STSPTPN2 | |
| SCHEMBL7985552 | 0.83 | KDM4E (0.69) | KDM4EPKMTGFBR1KDM1AGPR119 | |
| SCHEMBL17796229 | 0.83 | KDM4E (0.72) | KDM4EPKMTGFBR1KDM1AGPR119 | |
| SCHEMBL22716661 | 0.83 | KDM4E (0.61) | KDM4EPKMTGFBR1KDM1AGPR119 | |
| SCHEMBL30703662 | 0.83 | KDM4E (0.61) | KDM4EPKMTGFBR1KDM1AGPR119 | |
| SCHEMBL17796140 | 0.83 | KDM4E (0.56) | KDM4EPKMTGFBR1KDM1AGPR119 | |
| SCHEMBL17796145 | 0.82 | CXCR4 (0.48) | KDM4EPKM | |
| SCHEMBL18928181 | 0.81 | USP30 (0.53) | KDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771351-B2 | Wnt signaling inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20160168125-A1 | WNT SIGNALING INHIBITOR | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3028703-A1 | Wnt SIGNALING INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168125-A1 | WNT SIGNALING INHIBITOR | WNT3A, WNT1, WNT3 | KDM4E 1585/4885PKM 4368/4885TGFBR1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.